In a patient with Crohn's disease and psoriatic arthritis who discontinued methotrexate, would restarting methotrexate at the prior weekly dose keep his Crohn's disease under control?

Methotrexate Likely Would NOT Have Kept Crohn's Disease Under Control After Discontinuation

Restarting methotrexate at the prior weekly dose would likely maintain Crohn's disease remission only if the patient had initially achieved remission WITH methotrexate and is restarting it as maintenance therapy. However, the evidence shows methotrexate is specifically effective for maintenance of remission in patients whose active disease responded to methotrexate induction therapy—not as a standalone treatment after discontinuation 1, 2, 3.

Key Evidence-Based Considerations

Methotrexate's Role in Crohn's Disease

The British Society of Gastroenterology guidelines clearly state that methotrexate (15-25 mg IM weekly) is effective for patients whose active disease has responded to IM methotrexate 1. This is a critical distinction: methotrexate works for maintenance specifically in patients who achieved remission through methotrexate induction.

The 2019 BSG guidelines reinforce that methotrexate should not be used as monotherapy for induction of remission 2. The landmark trial showed methotrexate 25 mg weekly was effective for chronic active Crohn's disease in patients already on prednisolone for at least 3 months 2.

Maintenance Efficacy Data

Intramuscular methotrexate 15 mg weekly maintains remission in patients who responded to initial methotrexate therapy 4, 5. The pivotal North American Crohn's Study showed 65% of patients maintained remission at 40 weeks on 15 mg IM weekly versus 39% on placebo 4. However, this was specifically in patients who had achieved remission after 16-24 weeks of 25 mg weekly methotrexate induction 4.

Critical Dosing and Route Requirements

Subcutaneous administration has superior bioavailability compared to oral methotrexate, particularly at doses above 15 mg 2. The guidelines recommend:

• Induction: 25 mg subcutaneous/IM weekly for 16-24 weeks 1, 2, 3
• Maintenance: At least 15 mg weekly 2, 3
• Route: Subcutaneous preferred for induction; can switch to oral for maintenance with option to revert if effectiveness lost 2

Oral methotrexate at low doses (12.5 mg weekly) showed no statistically significant benefit over placebo 5. The Cochrane review found low-dose oral methotrexate (12.5-15 mg/week) does not appear effective for maintenance of remission 5.

The Psoriatic Arthritis Complication

This patient has both Crohn's disease and psoriatic arthritis. While methotrexate is highly effective for psoriatic arthritis 6, the dosing and monitoring requirements differ between specialties:

• Psoriasis/PsA: 7.5-25 mg weekly oral or subcutaneous 6
• Crohn's disease: 25 mg subcutaneous for induction, 15-25 mg for maintenance 1, 2, 3

The patient was likely on methotrexate primarily for psoriatic arthritis, not Crohn's disease, given the different treatment paradigms.

Why Restarting May Not Work

The evidence shows methotrexate maintains remission achieved BY methotrexate, not remission achieved by other means 1, 2, 4. If the patient:

1. Discontinued methotrexate while in remission
2. Subsequently developed active Crohn's disease
3. Now wants to restart methotrexate

This scenario differs from the studied populations. The patient would need:

• Re-induction with 25 mg subcutaneous weekly for 16-24 weeks 2, 3
• Then maintenance with 15-25 mg weekly 1, 2
• Not simply restarting the prior dose

Alternative Considerations

The 2019 BSG guidelines recommend azathioprine or mercaptopurine as first-line agents for steroid-dependent disease 1, 2. Methotrexate is appropriate for those intolerant of or who failed thiopurines 1, 2.

The 2025 AGA guidelines note thiopurines are not effective for induction but are effective for maintenance 3. For moderate-to-severe active Crohn's disease, biologics (anti-TNF therapy) are more effective than immunomodulators 2.

Common Pitfalls

• Assuming methotrexate works universally for Crohn's maintenance: It specifically maintains remission achieved through methotrexate induction 1, 2, 4
• Using inadequate doses: Oral methotrexate <15 mg weekly is ineffective 2, 5
• Wrong route of administration: Subcutaneous is superior for induction 2
• Treating as monotherapy without prior response: Guidelines specify use after methotrexate-induced remission 1, 2

Folic acid supplementation (5 mg weekly or 1 mg daily) is mandatory to reduce gastrointestinal and liver toxicity 2.